High mobility group protein AT-hook 1 (HMGA1) is associated with the development of androgen independence in prostate cancer cells

Prostate

Volumn 72, Issue 10, 2012, Pages 1124-1132

  Takeuchi, Ichiro ^a   Takaha, Natsuki ^a   Nakamura, Terukazu ^a   Hongo, Fumiya ^a   Mikami, Kazuya ^a   Kamoi, Kazumi ^a   Okihara, Koji ^a   Kawauchi, Akihiro ^a   Miki, Tsuneharu ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

androgen deprivation; androgen independence; castration resistant; HMGA1; prostate cancer

Indexed keywords

ANDROGEN; HIGH MOBILITY GROUP PROTEIN; HIGH MOBILITY GROUP PROTEIN AT HOOK 1; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; WESTERN BLOTTING;

ANDROGENS; ANIMALS; CELL LINE, TUMOR; GENE KNOCKDOWN TECHNIQUES; HMGA1A PROTEIN; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; PROSTATIC NEOPLASMS;

EID: 84861574201     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22460     Document Type: Article

References (25)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ,. Cancer statistics, 2009. CA Cancer J Clin 2009; 59 (4): 225-249.
2. Fusco A, Fedele M,. Roles of HMGA proteins in cancer. Nat Rev Cancer 2007; 7 (12): 899-910.
3. Reeves R, Nissen MS,. The A.T-DNA-binding domain of mammalian high mobility group I chromosomal proteins. A novel peptide motif for recognizing DNA structure. J Biol Chem 1990; 265 (15): 8573-8582.
4. Frasca F, Rustighi A, Malaguarnera R, Altamura S, Vigneri P, Del Sal G, Giancotti V, Pezzino V, Vigneri R, Manfioletti G,. HMGA1 inhibits the function of p53 family members in thyroid cancer cells. Cancer Res 2006; 66 (6): 2980-2989.
5. Ueda Y, Watanabe S, Tei S, Saitoh N, Kuratsu J, Nakao M,. High mobility group protein HMGA1 inhibits retinoblastoma protein-mediated cellular G0 arrest. Cancer Sci 2007; 98 (12): 1893-1901.
6. Chiappetta G, Avantaggiato V, Visconti R, Fedele M, Battista S, Trapasso F, Merciai BM, Fidanza V, Giancotti V, Santoro M, Simeone A, Fusco A,. High level expression of the HMGI (Y) gene during embryonic development. Oncogene 1996; 13 (11): 2439-2446.
7. Evans A, Lennard TW, Davies BR,. High-mobility group protein 1(Y): Metastasis-associated or metastasis-inducing? J Surg Oncol 2004; 88 (2): 86-99.
8. Tamimi Y, van der Poel HG, Denyn MM, Umbas R, Karthaus HF, Debruyne FM, Schalken JA,. Increased expression of high mobility group protein I(Y) in high grade prostatic cancer determined by in situ hybridization. Cancer Res 1993; 53 (22): 5512-5516.
9. Tamimi Y, van der Poel HG, Karthaus HF, Debruyne FM, Schalken JA,. A retrospective study of high mobility group protein I(Y) as progression marker for prostate cancer determined by in situ hybridization. Br J Cancer 1996; 74 (4): 573-578.
10. Takaha N, Hawkins AL, Griffin CA, Isaacs WB, Coffey DS,. High mobility group protein I(Y): A candidate architectural protein for chromosomal rearrangements in prostate cancer cells. Cancer Res 2002; 62 (3): 647-651.
11. Takaha N, Resar LM, Vindivich D, Coffey DS,. High mobility group protein HMGI(Y) enhances tumor cell growth, invasion, and matrix metalloproteinase-2 expression in prostate cancer cells. Prostate 2004; 60 (2): 160-167.
12. Leman ES, Madigan MC, Brunagel G, Takaha N, Coffey DS, Getzenberg RH,. Nuclear matrix localization of high mobility group protein I(Y) in a transgenic mouse model for prostate cancer. J Cell Biochem 2003; 88 (3): 599-608.
13. Pflug BR, Reiter RE, Nelson JB,. Caveolin expression is decreased following androgen deprivation in human prostate cancer cell lines. Prostate 1999; 40 (4): 269-273.
14. Kolb S, Fritsch R, Saur D, Reichert M, Schmid RM, Schneider G,. HMGA1 controls transcription of insulin receptor to regulate cyclin D1 translation in pancreatic cancer cells. Cancer Res 2007; 67 (10): 4679-4686.
15. Bussemakers MJ, van de Ven WJ, Debruyne FM, Schalken JA,. Identification of high mobility group protein I(Y) as potential progression marker for prostate cancer by differential hybridization analysis. Cancer Res 1991; 51 (2): 606-611.
16. Ji YS, Xu Q, Schmedtje JF Jr., Hypoxia induces high-mobility-group protein I(Y) and transcription of the cyclooxygenase-2 gene in human vascular endothelium. Circ Res 1998; 83 (3): 295-304.
17. Cmarik JL, Li Y, Ogram SA, Min H, Reeves R, Colburn NH,. Tumor promoter induces high mobility group HMG-Y protein expression in transformation-sensitive but not-resistant cells. Oncogene 1998; 16 (26): 3387-3396.
18. Pellacani A, Chin MT, Wiesel P, Ibanez M, Patel A, Yet SF, Hsieh CM, Paulauskis JD, Reeves R, Lee ME, Perrella MA,. Induction of high mobility group-I(Y) protein by endotoxin and interleukin-1beta in vascular smooth muscle cells. Role in activation of inducible nitric oxide synthase. J Biol Chem 1999; 274 (3): 1525-1532.
19. Wood LJ, Mukherjee M, Dolde CE, Xu Y, Maher JF, Bunton TE, Williams JB, Resar LM,. HMG-I/Y, a new c-Myc target gene and potential oncogene. Mol Cell Biol 2000; 20 (15): 5490-5502.
20. Massaad-Massade L, Navarro S, Krummrei U, Reeves R, Beaune P, Barouki R,. HMGA1 enhances the transcriptional activity and binding of the estrogen receptor to its responsive element. Biochemistry 2002; 41 (8): 2760-2768.
21. Debes JD, Tindall DJ,. Mechanisms of androgen-refractory prostate cancer. N Engl J Med 2004; 351 (15): 1488-1490.
22. Sun S, Sprenger CC, Vessella RL, Haugk K, Soriano K, Mostaghel EA, Page ST, Coleman IM, Nguyen HM, Sun H, Nelson PS, Plymate SR,. Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest 2010; 120 (8): 2715-2730.
23. Watson PA, Chen YF, Balbas MD, Wongvipat J, Socci ND, Viale A, Kim K, Sawyers CL,. Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci USA 2010; 107 (39): 16759-16765.
24. Nadiminty N, Chun JY, Lou W, Lin X, Gao AC,. NF-kappaB2/p52 enhances androgen-independent growth of human LNCaP cells via protection from apoptotic cell death and cell cycle arrest induced by androgen-deprivation. Prostate 2008; 68 (16): 1725-1733.
25. Shimada K, Nakamura M, De Velasco MA, Tanaka M, Ouji Y, Konishi N,. Syndecan-1, a new target molecule involved in progression of androgen-independent prostate cancer. Cancer Sci 2009; 100 (7): 1248-1254.